Compare LXRX & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXRX | PDX |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | NY |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 895.0M |
| IPO Year | 2000 | 2018 |
| Metric | LXRX | PDX |
|---|---|---|
| Price | $1.60 | $20.45 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.55 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 114.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.10 | $18.47 |
| 52 Week High | $2.68 | $22.59 |
| Indicator | LXRX | PDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 45.15 |
| Support Level | $1.50 | $19.98 |
| Resistance Level | $1.81 | $21.85 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.20 | 52.29 |
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.